Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: Central and peripheral components
- First Online:
- Cite this article as:
- Laird, J., Herrero, J., Garcia de la Rubia, P. et al. Inflamm. res. (1997) 46: 203. doi:10.1007/s000110050174
- 172 Downloads
Objective and Design: To study the characteristics and site of the analgesic action of meloxicam.¶Subjects: Adult female Wistar rats.¶Treatment: Monoarthritis was induced (for behavioural studies) by injection of complete Freund's adjuvant into the ankle. Meloxicam was given for 5 days (0.1–4 mg/kg/day i.p.). Inflammation of the knee or paw (for electrophysiology) was induced with carrageenan. Meloxicam was given i.v. (4–64 mg/kg).¶Methods: Rats were tested daily for joint hyperalgesia, and hindlimb posture (behaviour). At post-mortem, joint stiffness, oedema and gastric lesions were assessed. In anaesthetised rats, nociceptive reflex responses to stimulation of the paw were compared (electrophysiology). Statistics were performed using one-way analysis of variance.¶Results: Meloxicam reduced swelling and stiffness of the inflamed joint, joint hyperalgesia (ID50 = 0.4 ± 0.4 mg/kg/day) and spontaneous pain-related behaviour. It also inhibited peripherally mediated reflex responses to stimulation of inflamed tissue (ID50 = 7.6 ± 0.8 mg/kg i.v.) without affecting centrally mediated reflexes.¶Conclusions: Systemic meloxicam produces analgesia largely via peripheral mechanisms. The rapidity of its actions indicates a direct effect on sensitised nociceptors.